Beta-Caryophyllene, a CB2R Selective Agonist, Protects Against Cognitive Impairment Caused by Neuro-inflammation and Not in Dementia Due to Ageing Induced by Mitochondrial Dysfunction
- 1 December 2021
- journal article
- research article
- Published by Bentham Science Publishers Ltd. in CNS & Neurological Disorders - Drug Targets
- Vol. 20 (10), 963-974
- https://doi.org/10.2174/1871527320666210202121103
Abstract
Background: Dementia is a neurodegenerative disorder majorly evidenced by cognitive impairment. Although there are many types of dementia, the common underlying etiological factors in all the types are neuro-inflammation or aging induced apoptosis. β-caryophyllene, a cannabinoid type-2 receptor agonist, has been reported to have promising neuroprotective effects in cerebral ischemia and neuro-inflammation. Objective: In the present study, we evaluated the effects of β-caryophyllene against animal models of dementia whose etiology mimicked neuro-inflammation and aging. Methods: Two doses (50 and 100 mg/kg of body weight) of β-caryophyllene given orally were tested against AlCl3-induced dementia in male Sprague Dawley (SD) rats using the Morris water maze test. Subsequently, the effect of the drug was assessed for episodic memory in female SD rats using novel object recognition task in doxorubicin-induced neuro-inflammation and chemobrain model. Moreover, its effects were evaluated in D-galactose-induced mitochondrial dysfunction leading to dementia. Results: β-caryophyllene, at both doses, showed significant improvement in memory when assessed using parameters like target quadrant entries, escape latency and path efficiency in the Morris water maze test for spatial memory. In the doxorubicin-induced chemobrain model, β-caryophyllene at 100 mg/kg significantly elevated acetylcholinesterase and catalase levels and lowered lipid peroxidation compared to the disease control. In the novel object recognition task, β-caryophyllene at 100 mg/kg significantly improved recognition index and discrimination index in the treated animals compared to the disease control, with a significant increase in catalase and a decrease in lipid peroxidation in both hippocampus and frontal cortex. However, in the D-galactose-induced mitochondrial dysfunction model, β-caryophyllene failed to show positive effects when spatial memory was assessed. It also failed to improve D-galactose-induced diminished mitochondrial complex I and II activities. Conclusion: Hence, we conclude that β-caryophyllene at 100 mg/kg protects against dementia induced by neuro-inflammation with no effect on neuronal aging induced by mitochondrial dysfunction.Keywords
This publication has 52 references indexed in Scilit:
- Cannabinoid Receptor CB2 Modulates Axon GuidancePLOS ONE, 2013
- Is There a Causal Link between Inflammation and Dementia?BioMed Research International, 2013
- Confronting chemobrain: an in-depth look at survivors’ reports of impact on work, social networks, and health care responseJournal of Cancer Survivorship, 2009
- CB2 receptor activation attenuates microcirculatory dysfunction during cerebral ischemic/reperfusion injuryMicrovascular Research, 2009
- Emerging strategies for exploiting cannabinoid receptor agonists as medicinesBritish Journal of Pharmacology, 2009
- Modulation of the balance between cannabinoid CB1 and CB2 receptor activation during cerebral ischemic/reperfusion injuryNeuroscience, 2008
- Endocannabinoids and cannabinoid receptors in ischaemia–reperfusion injury and preconditioningBritish Journal of Pharmacology, 2008
- Cannabinoid CB2Receptor Activation Decreases Cerebral Infarction in a Mouse Focal Ischemia/Reperfusion ModelJournal of Cerebral Blood Flow & Metabolism, 2007
- Mitochondrial dysfunction and oxidative stress in neurodegenerative diseasesNature, 2006
- Mitochondrial ND5 mutations in idiopathic Parkinson’s diseaseBiochemical and Biophysical Research Communications, 2005